Celltrion has received a formal approval from the European Commission extending the marketing authorization for its Remsima SC (infliximab) subcutaneous biosimilar to cover an additional five indications on top of the rheumatoid arthritis indication for which it was initially approved.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?